How to access Wainzua from Bahrain, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Bahraini patient diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Wainzua (eplontersen) from their treating neurologist in a tertiary centre in Riyadh, Jeddah, or the Eastern Province. Wainzua is FDA-approved for this indication and developed by Ionis Pharmaceuticals in partnership with AstraZeneca. In Bahrain, Wainzua is not routinely registered for outpatient dispensing for this indication, and access is typically coordinated through the named-patient import pathway.
This guide explains the legal pathway, documentation your neurologist prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Wainzua is a ligand-conjugated antisense oligonucleotide (LICA-ASO) that silences hepatic TTR production, administered subcutaneously once monthly via auto-injector. Eligibility requires genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy, and workup to characterise any cardiac amyloidosis overlap. Your neurologist will establish baseline neuropathy impairment score, mNIS+7, polyneuropathy disability score, and quality-of-life measures. Wainzua's self-administration profile is a meaningful convenience advantage, patients can self-inject at home after clinic training.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Wainzua legally importable into Bahrain?
Yes, through the National Health Regulatory Authority (NHRA) named-patient / special-access import framework. The mechanism permits a KSA-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented. hATTR polyneuropathy has limited disease-specific registered options on Bahrain formularies, which simplifies clinical rationale.
How the pathway works, step by step
- Consultation with your treating neurologist. TTR genetic report, neuropathy scoring, and clinical rationale.
- Baseline assessment. mNIS+7, polyneuropathy disability score, cardiac workup (ECG, echocardiogram, NT-proBNP).
- NHRA named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing schedule, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Wainzua from authorised distribution under DSCSA.
- Cold-chain shipment. Wainzua requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging.
- Arrival and dispensing. The hospital pharmacy releases the auto-injector to the patient after clinic-based self-administration training.
What documentation your physician needs
- Clinical rationale letter confirming hATTR polyneuropathy and Wainzua as the indicated therapy
- Verification of Bahrain medical license (SCFHS)
- TTR genetic test result
- Baseline mNIS+7 and polyneuropathy disability score
- Cardiac assessment for ATTR-CM overlap
- Planned monthly dosing schedule and monitoring plan
Reserve Meds provides a physician documentation kit bundling templates NHRA reviewers expect for rare-disease neurology named-patient imports.
Costs and timing
Wainzua's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 440,000-470,000 (dosed monthly). International logistics, NHRA documentation handling, cold-chain shipment, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.
Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete NHRA application is submitted.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Mechanism, approval status, and treatment course
Wainzua (eplontersen) is a ligand-conjugated antisense oligonucleotide (LICA) that binds transthyretin (TTR) mRNA and triggers RNase-H-mediated degradation, reducing both wild-type and variant TTR protein production at the hepatocyte source. FDA approval: 2023. EMA approval: 2024. The labelled indication is the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adults. Wainzua is supplied through the US specialty distribution channel only; Reserve Meds sources from a US-licensed authorised wholesaler under Drug Supply Chain Security Act (DSCSA) chain-of-custody and ships under the documentation framework NHRA reviewers expect.
Dosing. Subcutaneous 45 mg once monthly via single-use auto-injector. Self-administered after training, or administered by a caregiver or clinic nurse. No loading dose; first dose is the maintenance dose. The Bahraini treating physician documents the planned dose, the titration interval, and the response endpoint in the NHRA application package.
Tertiary referral landscape in Bahrain
Wainzua cases in Bahrain are most commonly initiated and followed at tertiary referral centres with subspecialty expertise in the indication. These include King Hamad University Hospital, Bahrain Specialist Hospital, and Salmaniya Medical Complex. The treating physician of record (the Bahraini-licensed neurologist, haematologist, or relevant subspecialist) holds clinical responsibility for the case; Reserve Meds does not interpose between the patient and the prescriber. NHRA pathway submissions are filed by the treating physician or the hospital pharmacy department, and Reserve Meds supplies the regulatory documentation package that NHRA reviewers expect.
Where the patient is followed at a non-tertiary clinic, the patient is typically referred for the Wainzua initiation visit to one of the centres above and then returns to local follow-up with monthly or quarterly tertiary review, depending on the clinical picture. Reserve Meds coordinates the refill cadence so that the next shipment is in country at least 7 days before the patient's current supply ends.
Monitoring and continuity of care
The Bahraini treating physician follows a standard monitoring schedule once Wainzua is initiated:
- Serum TTR level at baseline and 3 months to document the expected 80 to 85 percent reduction confirming target engagement
- Neuropathy Impairment Score plus 7 (NIS+7) or equivalent at baseline and annually to track polyneuropathy progression
- Vitamin A supplementation is mandatory at the standard recommended daily allowance because TTR is the principal carrier of retinol-binding protein; ophthalmologic evaluation at baseline and annually
Reserve Meds is not involved in the clinical monitoring itself, but supplies refill cadence reminders to the patient and the treating physician so that the next-month supply is delivered in advance of the patient's next scheduled clinic visit. The first refill is shipped at week 3 of the initial cycle so that any titration adjustment from the 4-week visit can be reflected in the dose supplied for cycle 2.
Concomitant medications and safety considerations
Before Wainzua is initiated, the Bahraini treating physician reconciles every concomitant prescription, over-the-counter, and herbal medicine the patient is taking. Key safety points the physician documents in the NHRA package:
- Injection-site reactions (erythema, pain, pruritus) are the most common adverse event, typically mild and not requiring dose modification; the patient is taught injection-site rotation across four anatomic quadrants
- Thrombocytopenia and renal events have been reported with the broader antisense-oligonucleotide class; eplontersen-specific rates are lower than first-generation agents but quarterly complete blood count and serum creatinine remain prudent in the first year
- Vitamin A deficiency manifests as night-blindness or xerophthalmia and is fully preventable with the supplementation requirement above; the patient is counselled never to discontinue the vitamin A supplement
The patient is given a written counselling document in the language of care identifying which symptoms warrant immediate clinical contact and which can wait for the next scheduled visit. Reserve Meds supplies a generic counselling-document template that the treating physician adapts to the patient's case.
Funding considerations in Bahrain
Wainzua is supplied on a cash-pay basis. Some Bahraini private medical insurers consider named-patient imports of FDA-labelled medicines on a case-by-case basis, particularly when the insurer's medical director can review the clinical rationale letter and the NHRA authorisation. Reserve Meds supplies the documentation package the insurer requires for review but does not adjudicate or process claims directly.
For self-pay patients, Reserve Meds issues a transparent quote at intake covering the drug-only band, international logistics, NHRA documentation handling, and concierge case coordination. The quote is fixed for the duration of the initial 90-day cycle and re-issued for each subsequent cycle if the dose changes. Patients are encouraged to ask their Bahraini treating physician about manufacturer patient-assistance pathways where available, although most US manufacturer assistance programs are restricted to US residents.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and NHRA review.
- Logistics. Validated cold-chain shipment to your prescribing hospital pharmacy.
- Concierge case lead. A named point of contact coordinating monthly refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Bahrain? Yes, when executed through the NHRA named-patient framework with appropriate documentation. See our trust and compliance page.
How is Wainzua different from Amvuttra or Onpattro? All three silence hepatic TTR but differ in chemistry and administration, Wainzua is subcutaneous antisense (monthly, auto-injector), Amvuttra is subcutaneous siRNA (quarterly), Onpattro is intravenous siRNA (every three weeks). Your neurologist selects based on clinical picture and patient preference.
Can I self-inject at home? Yes, after clinic-based training on the auto-injector, consistent with FDA labeling.
Will insurance cover this? Cash-pay is the default. Some Bahrain private insurers consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
How does Wainzua differ from inotersen and patisiran and vutrisiran? All four target TTR, but they differ in mechanism and route. Inotersen and eplontersen are antisense oligonucleotides; eplontersen is the ligand-conjugated successor with monthly subcutaneous dosing and a cleaner platelet profile. Patisiran and vutrisiran are small interfering RNAs; patisiran is intravenous every three weeks, vutrisiran is subcutaneous every three months. The neurologist selects based on cardiac involvement, dosing preference, and access channel.
Does Wainzua treat the cardiomyopathy component of ATTR? The current FDA label is for polyneuropathy. The CARDIO-TTRansform cardiomyopathy trial completed in 2025; label expansion is anticipated but not yet active as of 2026. The treating cardiologist and neurologist co-manage patients with mixed phenotype.
Can the patient continue tafamidis while on Wainzua? Combination use is not labelled. Most experienced ATTR centres select one TTR-stabilising or TTR-lowering agent rather than combining, given uncertain incremental benefit and additional cost. The treating physician makes this decision case by case.
How long is the patient expected to remain on Wainzua? Indefinitely, while clinical benefit persists and the patient tolerates the monthly injection. ATTR is a progressive disease and TTR lowering is a maintenance therapy, not a curative one-time intervention.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.